Literature DB >> 16339237

Drug companies told that sponsoring patients' groups might help win approval for their products.

Bob Burton.   

Abstract

Entities:  

Mesh：

Year:  2005        PMID： 16339237      PMCID： PMC1309681          DOI： 10.1136/bmj.331.7529.1359-b

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  4 in total

1.  Patient organisations and the reimbursement process for medicines: an exploratory study in eight European countries.

Authors:  Janneke Noordman; Liset van Dijk; Roland Friele
Journal:  BMC Health Serv Res       Date:  2010-02-22       Impact factor: 2.655

2.  Patient advocacy organizations: institutional conflicts of interest, trust, and trustworthiness.

Authors:  Susannah L Rose
Journal:  J Law Med Ethics       Date:  2013       Impact factor: 1.718

3.  Advertising and disclosure of funding on patient organisation websites: a cross-sectional survey.

Authors:  Douglas E Ball; Klara Tisocki; Andrew Herxheimer
Journal:  BMC Public Health       Date:  2006-08-03       Impact factor: 3.295

4.  Association between commercial funding of Canadian patient groups and their views about funding of medicines: An observational study.

Authors:  Joel Lexchin
Journal:  PLoS One       Date:  2019-02-15       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.